

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

The cold eye irrigation BSS solution used during phacoemulsification reduces post-surgery patients discomfort preventing the inflammation

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1789505> since 2021-06-03T13:59:30Z

Published version:

DOI:10.1177/11206721211018377

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



The cold eye irrigation BSS solution used during phacoemulsification reduces post-surgery patients discomfort preventing the inflammation.

Journal:	<i>European Journal of Ophthalmology</i>
Manuscript ID	EJO-20-1635.R1
Manuscript Type:	Original Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Meduri, Alessandro; University of Messina, BERGANDI, LOREDANA; University of Turin Oliverio, Giovanni; University of Messina Rechichi, Miguel; Cataract and refractive surgeon crosslinking specialist Acri, Giuseppe; University of Messina Perroni, Pietro; Oftalmico Hospital, ASSt-Fatebenefratelli-Sacco Silvagno, Francesca; University of Turin Aragona, Pasquale; University of Messina
Keywords:	Biochemistry/Physiology < LENS / CATARACT, Practice management < SOCIOECONOMICS AND EDUCATION IN MEDICINE/OPHTHALMOLOGY, Phacoemulsification < LENS / CATARACT, Anti-inflammatory Agents < CORNEA / EXTERNAL DISEASE, Examination Techniques < CORNEA / EXTERNAL DISEASE
Abstract:	<p>Purpose: The aim of this study was to assess whether the intraoperative use of the cold eye irrigation balanced salt solution (BSS) could have a protective effect in preventing the anterior chamber flare and conjunctival hyperemia and, thus, reducing patients discomfort after phacoemulsification.</p> <p>Materials and methods: 214 patients were enrolled and randomly divided into: patients whose eye were irrigated with BSS at ~ 20 ° C (Group 1) and patients whose eye were irrigated with BSS at 2.7 ° C (Group 2).</p> <p>Results: In patients of Group 2 the anterior chamber flare, the visual analogue score and the conjunctival hyperemia, used as parameters to evaluated clinical inflammation, at 1 day after surgery were significantly lower than of those in Group 1 who received BSS solution at operating room temperature ($p < 0.001$), while at day 3, 5 and 30 there were not any significant differences.</p> <p>Conclusion: Our study provided evidence supporting the efficacy of the treatment with cold irrigation solution on reduction of anterior chamber flare, pain and conjunctival hyperemia already at 1 day after phacoemulsification suggesting that cooling procedure was fully effective at controlling early post-operative inflammation.</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 **The cold eye irrigation BSS solution used during phacoemulsification reduces**
4 **post-surgery patients discomfort preventing the inflammation.**
5
6
7
8
9
10

11 4 Alessandro Meduri¹ MD, PhD, Loredana Bergandi² PhD, Giovanni William Oliviero¹
12 MD, Miguel Rechichi³ MD, PhD, Giuseppe Acri¹ MD, Pietro Perroni⁴ MD,
13 5
14 Francesca Silvagno² PhD, Pasquale Aragona¹ MD, PhD
15 6
16
17
18 7
19
20
21 8
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

9 ABSTRACT

10 ~~Purpose: The protection of endothelial cells and the controlling of post-operative~~
11 ~~inflammation are always one of the major issues in the cataract procedures, and new~~
12 ~~surgical alternatives to achieve this goal continue to be sought.~~ The aim of this study
13 was to assess whether the intraoperative use of the cold eye irrigation balanced salt
14 solution (BSS) ~~solution~~ could have a protective effect in preventing the anterior
15 chamber flare and conjunctival hyperemia and, thus, reducing patients discomfort
16 after phacoemulsification.

17 **Materials and methods:** 214 patients were enrolled and randomly divided into:
18 patients whose eye were irrigated with BSS at ~ ~~18.0~~ 20 ° C (Group 1) and patients
19 whose eye were irrigated with BSS at 2.7 ° C (Group 2). Anterior chamber flare,
20 visual analogue score and conjunctival hyperemia were evaluated at 1, 3, 5 and 30
21 day after surgery.

22 **Results:** In patients of Group 2 ~~the anterior chamber flare, the visual analogue score~~
23 ~~and the conjunctival hyperemia, used as all the clinical inflammation scores~~
24 ~~parameters to evaluated clinical inflammation, at 1 day after surgery were~~
25 significantly lower than of those in Group 1 who received BSS solution at operating
26 room temperature ($p < 0.001$), ~~while at day 3, 5 and 30 there were not any significant~~
27 ~~differences.~~

28 **Conclusion:** Our study provided evidence supporting the efficacy of the treatment
29 with cold irrigation solution on reduction of anterior chamber flare, pain and
30 conjunctival hyperemia ~~already at 1 day after phacoemulsification.~~ ~~The suggesting~~
31 ~~that~~ cooling procedure was fully effective at controlling ~~early~~ post-operative
32 inflammation.

33
34 **Keywords:** phacoemulsification; cold irrigation balanced salt solution; anterior
35 chamber flare; pain; conjunctival hyperemia

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

37 **Short title:** cold eye irrigation solution prevents post-surgery inflammation

38

39

For Peer Review

40 INTRODUCTION

41 Cataract is a significant cause of visual impairment and blindness worldwide (1) (2).
42 Nowadays, one of the most frequently performed surgeries is cataract and it is
43 considered an ordinary practice in the ophthalmological field (3). Although the safety
44 of the phacoemulsification technique has been markedly improved in terms of
45 refractive results (4) and of decrease in the physical trauma related with the surgical
46 procedure (5) (6) (7), the reduction of both the iatrogenic effects and the complication
47 rates on the eye is still an important issue for all cataract surgeons (1) (8) (9). Indeed
48 the surgical trauma-induced synthesis and release of inflammatory mediators have
49 not ~~been~~ fully eliminated (10). ~~However-a~~ Although inflammation is required in
50 ~~tissue healing is usually self-limited (11) for~~ due to the beneficial mediators produced
51 (12) (13) ~~and it is usually self-limited~~ (11), uncontrolled inflammation may cause
52 possible post-operative complications, such as increased intraocular pressure, cystoid
53 macular edema, posterior capsule opacification (14), rarely endophthalmitis,
54 secondary glaucoma (5), triggering discomfort or even severe pain to the patients (15)
55 (16), delayed recovery, and possible suboptimal visual results (17) (18) (19).
56 Adverse effects at cellular and subcellular level that can contribute to ocular
57 inflammation during cataract surgery are attributed to mechanical, thermal, and
58 chemical mechanisms. Surgical instruments contact and turbulent fluids which are
59 generated by the phaco tip's jackhammer effect are the causes of mechanical injury
60 (20) (21), while high frequency ultrasound vibration at the tip or ~~by-an~~ occlusion of
61 the tip caused by the lens fragmentation during the emulsification are the causes of
62 the thermal injury (22) (21). The imploding of cavitation bubbles that are generated
63 during the procedure causes a chemical damage that is mediated by free radicals
64 formed in the aqueous humor (23) (21).
65 Notably, we previously demonstrated that the use of an intraoperative cold solution
66 irrigating the eye improves the outcome of this widely ~~praetised~~ ~~practiced~~ surgical
67 intervention; ~~in fact, when the as in patients whose~~ eyes were irrigated with balanced
68 salt solution (BSS) at 2.7° C, ~~in these patients~~ the corneal endothelial density was

1
2
3 69 significantly higher than ~~the density measured of these~~ in patients who received BSS
4
5 70 solution at operating room temperature, ~~therefore cold irrigation ensuring ensures~~ a
6
7 71 less traumatic surgical procedure (24). However, if the cooling procedure is
8
9 72 protective against cells loss in patients affected by cataract, the focus of ~~our-the~~
10
11 73 ~~previous study~~ has not been ~~paid on~~ pain or ~~on~~ other post-operative ocular symptoms.
12
13 74 This aspect is of a relevant importance ~~at the light considering~~ that patients should ~~be~~
14
15 75 ~~provided receive~~ not only appropriate counseling on pain, but also ~~support on~~ pain
16
17 76 management as part of routine intraoperative care to reduce afflictions and problems
18
19 77 ~~arise-arising~~ after the hospital discharge.

20
21 78 The aim of this study was to assess whether the intraoperative use of a cold solution
22
23 79 irrigating the eye could be helping patients alleviate the post-operative discomfort
24
25 80 due to cataract surgery. For this purpose, in 214 patients which underwent cataract
26
27 81 surgery with phacoemulsification, ~~at 1, 3, 5 and 30 days after surgery~~, we assessed
28
29 82 the post-operative effects, on the anterior chamber flare, the pain and conjunctival
30
31 83 hyperemia of intraoperative BSS at two different temperature: at ~~~18 20~~ °C, that is
32
33 84 the average temperature of the operating room, and at 2.7 °C.
34
35 85
36
37 86
38
39 87
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

88 MATERIAL and METHODS

89 The study was carried out in accordance with the Declaration of Helsinki for medical
90 research involving human subjects and was authorized by the local Ethical
91 Committee (number 43/19-0006654). Signed, informed and written consent was
92 obtained from all patients accepting to be included in this study.

93 Two hundred fourteen otherwise healthy patients were randomly enrolled among
94 patients that had to undergo cataract surgery from the central vitreous cavity, with an
95 average age of 65 ± 7.3 (range: from 55 to 75) of both sexes. Different levels of
96 cataracts were recruited, mainly middle degree (2/3) according to the classification of
97 Lens Opacities Classification System III (LOCSIII) (25) (26).

98 The exclusion criteria from the study were: glaucoma, infections, autoimmune
99 diseases, proliferative diabetic retinopathy, previous corneal diseases or any ocular
100 surgical procedures, and malignant ~~neoplasias neoplasms~~ (24).

101 Three days prior to the cataract surgery, 1 % sodium hypochlorite 2X/day, 0.3 % ~~and~~
102 ofloxacin 1 gtt 3X/day ~~and bromfenac (0.9 mg/ml) 1 gtt 2X/day~~ were the medical
103 treatments for all the patients. Topical ~~medicartillary insertion based~~ on tropicamide
104 and phenylephrine (0.28 mg/5.4 mg) (Mydriaser®[®], Thèa Farma S.p.A., Milan, Italy)
105 were used in all the patients (24). ~~All patients were given benoxinate 0.4% drops 4~~
106 ~~times at 3-minute intervals before surgery.~~

107 214 patients were enrolled and therefore randomly divided into: patients whose eye
108 were irrigated with BSS ~~maintained at room temperature in the operating room (about~~
109 ~~20 °C)~~ (Group 1) ($n = 110$ eyes of 110 patients) and patients whose eye irrigated with
110 BSS at 2.7 ° C (Group 2) ($n = 104$ eyes of 104 patients). Cataract surgeries were
111 carried out with different intensity setups on the basis of the cataract degree (24) by
112 the same surgeon using a traditional OPMI Lumera 700 microscope (Carl Zeiss
113 Vision Italia, S.p.A., Varese, Italy) and a SIGNATURE[®] Phacoemulsification System
114 (Johnson & Johnson Vision Medical SpA, Pomezia - Roma, Italy) was used (24). A
115 sample of patients was evaluated for anterior chamber temperature; measurements
116 were obtained using the FLIR T440 (FLIR Systems AB, Wilsonville, USA).

1
2
3 117 In the post-operative period, each patient was treated with a combination of cortisone
4
5 118 and antibiotics (betamethasone - chloramphenicol) 4X/day for 1 month, artificial
6
7 119 tears (Ialuvit®) (Alfa Intes Industria Terapeutica Splendore S.r.l., Naples, Italy)
8
9 120 4X/day for 1 month and bromfenac (0.9 mg/ml) 3X/day for a month.

11 121 All patients underwent an ophthalmologic assessment including anterior chamber
12
13 122 flare, pain, and conjunctival hyperemia evaluation on days 1, 3, 5 and 30 after
14
15 123 cataract surgery. Neither the patients nor the same examiner was informed about the
16
17 124 temperature of BSS used during the cataract surgery.

21 126 *Clinical grade of anterior chamber flare*

23 127 Immediately after clinical assessment, patients had flare readings measured by an
24
25 128 experienced technician using the slit lamp, according to the manufacturer's guidelines
26
27 129 (27). ~~All patients were assessed by the same technician.~~ Based on SUN, the
28
29 130 standardization of uveitis nomenclature (28) (29) (30), the aqueous flare was graded
30
31 131 as follows: in the absence of any notable flare 0, for faint flare 1+, for moderate flare
32
33 132 (iris and lens details are clear) 2+, for marked flare (iris and lens details are hazy) 3+,
34
35 133 and for intense flare (fibrin in the aqueous humor) 4+ (31).

39 135 *Clinical grade of pain*

41 136 The average pain intensity was evaluated in each case using the Visual Analogue
42
43 137 Score (VAS) (32) (33). A modified VAS scale 100 cm in length (equivalent to 100
44
45 138 degrees) was used, with its numbers (degrees) being visible only on the side of the
46
47 139 examiner (34). The examiner explained to the patient that the 0 point represented no
48
49 140 pain and that the 100 point represented the most intense pain he or she felt throughout
50
51 141 the surgical procedure (34). Each patient was encouraged to pass the marker along
52
53 142 the scale and to point out to the number.

144 ***Clinical grade of conjunctival hyperemia***

145 Clinical grade of conjunctival hyperemia occurred at the temporal bulbar conjunctiva
146 was evaluated in each case on the basis of the number of dilated vessels the day post
147 surgery and at 30 ± 2 (SD) days (35). The palpebral conjunctiva is not evaluated. The
148 clinical grade scores were: none, no hyperemia of the bulbar conjunctiva 0; mild, the
149 dilation of a few conjunctival blood vessels (1), moderate, the dilation of some
150 conjunctival blood vessels (2) and severe, the dilation of many conjunctival blood
151 vessels (3), based on Japanese guidelines for allergic conjunctival disease (36) (35).
152 Clinical grades were evaluated by three medical ophthalmic physicians, using the
153 photographs taken at each of the 6 time points (35). The most frequent grade value
154 generated by the three physicians has been selected and, when the scores differed
155 among the technicians, the maximum value has been ~~chosen~~ chosen. The mean
156 score was used for the subsequent analysis. The degree of agreement among the three
157 observers regarding the conjunctival hyperemia scores was also evaluated (37).

159 ***Statistical analysis***

160 Based on the results of Shapiro-Wilk test of normality a parametric analysis was
161 carried out. Student's paired and unpaired t-test was applied to compare pre- and
162 post-surgery data for each group (intra-groups analysis) and pre- and post-surgery
163 data between the two groups data (inter-group analysis), respectively. Analysis were
164 performed using an open source R3.0 software package. Significance level was set at
165 $p= 0.05$. A power calculation was done using StatSoft software. The power of the
166 study, given a 1.5 fold change in flare, conjunctival hyperemia and VAS scores as a
167 significant difference between the groups, was calculated to be 85% with an $\alpha= 0.05$
168 and 100 randomly patients for each group enrolled.

1
2
3 169 Fleiss' κ factor using Microsoft Excel® XLSTAT (Redmond, WA, USA) (37) (38)
4
5 170 was used to assess the degree of agreement among the three observers for the anterior
6
7 171 chamber flare and conjunctival hyperemia scores.
8

11 173 RESULTS

13 174 The clinical study investigated the short (at 1 and 5 day after surgery) and long-term
14
15 175 (at 30 day after surgery) the effects of ~~the use using~~ during phacoemulsification of
16
17 176 two different temperatures of the BSS irrigating solutions on anterior chamber flare,
18
19 177 pain and conjunctival hyperemia, which are the most common post-operative
20
21 178 negative consequences after cataract surgeries.

23 179 Patients of Group 1, including 52 women and 58 men, received BSS solution at ~ 20
24
25 180 °C and patients of Group 2, including 49 women and 55 men, received BSS solution
26
27
28 181 at 2.7 °C. The two groups were comparable with respect to age, sex and education
29
30 182 grade ($p > 0.05$) (Table 1). Preoperative variables between the two groups were not
31
32 183 significantly different and no surgical complications, such as capsule rupture or
33
34 184 zonular dialysis in any eye, occurred. Particularly, in the group receiving cold BSS
35
36 185 we did not observed any macular edema, intraocular pressure spike or posterior
37
38 186 capsule opacification occurrence after surgery. None of the patients experienced
39
40 187 intraoperative pain or immediate postoperative pain.

42 188 At day 1 after surgery Group 2 presented a significant lower mean flare than in Group
43
44 189 1 ($p= 0.04$). At day 3, 5, and 30 after treatment a statistical significant reduction of
45
46 190 the mean flare evaluated at day 1 were observed in both groups; these measurements
47
48 191 were comparable between Group 1 and 2 ($p>0.05$) (Table 1 2).

50 192 Moreover, ~~t~~ The mean pain score in Group 2 was significantly decreased if compared
51
52 193 to Group 1 at day 1 after the surgery (Table 1 2). On the contrary, the mean pain
53
54 194 score between Group 1 and Group 2 at day 3, 5, and 30 after the surgery was not
55
56 195 significantly different (Table 2).

58 196 ~~Considering the recorded scores, eighty two (78 %) of 104 patients in Group 2~~
59
60 197 ~~considered the procedure less painful than patients in Group 1 in which seventy nine~~

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

~~(72 %) of 110 said surgery in the eye without cold intraocular irrigation was more painful.~~ Moreover, eighty-two patients (78%) in Group 2 reported a VAS score smaller than those recorded in Group 1 while seventy-nine patients (72%) in Group 1 reported a VAS score higher than those recorded in Group 2.

~~On the contrary, the mean pain score between Group 1 and Group 2 at day 30 after the surgery (Table 1) was not significantly different.~~

Furthermore, all patients of Group 2 showed a lower conjunctival hyperemia score at 1 day after the surgery, whereas at 3, 5 and 30 days the conjunctival hyperemia mean score of patients of Group 2 was equal to that of patients of Group 1. The κ coefficient (Fleiss' κ for the three observers) for the conjunctival hyperemia score grading in the right eye was moderate: 0.467 (95% confidence interval, 0.423–0.512).

~~At long term~~ In the long run, for each of the inflammation scores there ~~is-were~~ not significant differences between the two groups at 30 days after surgery.

212

	Patient whose eye were irrigated with BSS at ~20° C (Group 1) n = 110	Patient whose eye were irrigated with BSS at 2.7° C (Group 2) n = 104	
Gender			n.s.
Male	52	49	
Female	58	55	
Age (years)	69.02 ± 6	68.65 ± 7	n.s.
Nationality	italian	italian	n.s.
Education	0	0	n.s.
Primary	9	11	
Secondary	73	68	
Higher	28	25	

213

214 **Table 1.** A descriptive table of variables by groups. $p > 0.05$ (n.s.) Group 2 vs Group 1 before and
215 after treatments.

216

217

218

Variables	Group 1 (patients who received BSS solution at $\sim 18^{\circ}\text{C}$) n=110	Group 2 (patients who received BSS solution at 2.7°C) n=104	p-value
Flare at 1-day after surgery (photons/milliseconds)	2.83 ± 0.41	1.68 ± 0.18	0.043
Flare at 30-days after surgery (photons/milliseconds)	0.51 ± 0.29	0.46 ± 0.31	0.293
p-value	<0.0001	<0.0001	
VAS at 1-day after surgery (units)	6.72 ± 1.98	3.35 ± 2.12	<0.001
VAS at 30-days after surgery (units)	1.02 ± 0.77	0.95 ± 0.5	0.426
p-value	<0.0001	<0.0001	
conjunctival hyperemia at 1-day after surgery (units)	2.2 ± 0.77	1.5 ± 0.5	<0.0001
conjunctival hyperemia at 30-days after surgery (units)	0.6 ± 0.5	0.5 ± 0.5	0.1387
p-value	<0.0001	<0.0001	

219

220

221

Variables	Group 1 (patients who received BSS solution at with BSS at ~20° C) n = 110	Group 2 (patients who received BSS solution at 2.7°C) n = 104	p value
FLARE (photons/milliseconds)			
at 1 day after surgery	2.83 ± 0.41	1.68 ± 0.18	0.043
at 3 day after surgery	1.91 ± 0.61 ^a	1.18 ± 0.24 ^b	0.172
at 5 day after surgery	0.55 ± 0.31 ^c	0.53 ± 0.27 ^c	0.451
at 30 days after surgery	0.51 ± 0.29 ^d	0.46 ± 0.31 ^d	0.293
VAS (units)			
at 1 day after surgery	6.72 ± 1.98	3.35 ± 2.12	<0.001
at 3 day after surgery	3.64 ± 1.39 ^a	2.85 ± 1.55 ^a	0.273
at 5 day after surgery	1.82 ± 0.95 ^b	1.65 ± 1.12 ^b	0.390
at 30 days after surgery	1.02 ± 0.77 ^c	0.95 ± 0.5 ^c	0.426
CONJUNCTIVAL HYPEREMIA (units)			
at 1 day after surgery	2.2 ± 0.77	1.5 ± 0.5	<0.0001

at 3 day after surgery	1.1 ± 0.51^a	1.1 ± 0.49^b	0.250
at 5 day after surgery	0.8 ± 0.62^c	0.7 ± 0.62^c	0.110
at 30 days after surgery	0.6 ± 0.5^d	0.5 ± 0.5^d	0.139

Table 1 2. Comparison of inflammation scores (anterior chamber flare, VAS, visual analogue score and conjunctival hyperemia) between the two groups. **p value reported in table refers to intergroup comparison, and p values for intragroup comparison at different times after surgery are as follows:** ^a $p = 0.03$ (1 day vs 3 day); ^b $p = 0.04$ (1 day vs 3 day); ^c $p < 0.0001$ (1 day vs 5 day); ^d $p < 0.0001$ (1 day vs 30 day) for flare; ^a $p < 0.001$ (1 day vs 3 day); ^b $p < 0.0001$ (1 day vs 5 day); ^c $p < 0.0001$ (1 day vs 30 day) for VAS; ^a $p = 0.015$ (1 day vs 3 day); ^b $p = 0.01$ (1 day vs 3 day); ^c $p < 0.0001$ (1 day vs 5 day); ^d $p < 0.0001$ (1 day vs 30 day) for conjunctival hyperemia.

DISCUSSION

The use of ultrasounds during phacoemulsification can lead to endothelial cell damage due to mechanical trauma (39) and also to the onset of an intraocular inflammatory status (40). Stănilă et al. demonstrated that the excessive amount of ultrasound energy during phacoemulsification increases the temperature (9) leading to a reduction of about 20 % of the human corneal endothelial cells (41).

~~Even today the optimal temperature of solutions for intraocular surgery, especially phacoemulsification, is controversial and the benefit of hypothermia during cataract surgery remains questionable (42). As our~~ Our previous study has demonstrated that the use of a cold irrigation solution has a fundamental role in decreasing the damage of corneal endothelial cells during phacoemulsification (24). Indeed, in post-operative we found a significant reduction of the loss of corneal endothelial cell density in patients treated with BSS at 2.7 °C compared to those were treated with BSS at ~ 18 20 °C (24). Most strikingly, we observed that in patients affected by softer cataract, who require a percentage of ultrasounds less than 10 % of the maximum power, the corneal endothelial cell density was not significantly different in pre- and post-

1
2
3 248 surgery when BSS was applied at cold temperature. Even in patients affected by
4
5 249 medium and hard cataract and treated with higher ultrasound power (from 10 to 29
6
7 250 %) we ~~assisted to detected~~ a significant corneal endothelial cell ~~density saving~~
8
9 251 ~~survival~~ when BSS 2.7°C was used (24).

10
11 252 Although we ~~well clearly~~ established that the cooling of the irrigation solution during
12
13 253 phacoemulsification prevents, ~~almost in part, the~~ endothelial damage, we had not ~~any~~
14
15 254 ~~evidence of investigated~~ the beneficial effects of a cold irrigating solution on the
16
17 255 post-operative discomfort. Indeed, it is well known that changes in the integrity of the
18
19 256 endothelium might result in edema (34) and, subsequently, in corneal opacity with
20
21 257 associated visual loss (21) accompanied by a painful, debilitating foreign body
22
23 258 sensation (42).

24
25 259 ~~Praveen et al. reported that the use of moderately cooled BSS Plus does not affect~~
26
27 260 ~~post-operative corneal parameters and inflammation showing no detectable effect and~~
28
29 261 ~~benefit on the outcome of phacoemulsification (43). This could be ascribed to the~~
30
31 262 ~~composition of the BSS Plus; Even if ocular tissue is highly sensitive to depletion of~~
32
33 263 ~~cellular glutathione that can result in inflammation and cell apoptosis, the possible~~
34
35 264 ~~beneficial effect of glutathione supplementation has not been proven. as antioxidant~~
36
37 265 ~~molecule maintains the junctional complexes of corneal endothelial cells and protects~~
38
39 266 ~~the blood-aqueous barrier integrity acting as inflammatory response modulator.~~
40
41 267 ~~Indeed ocular tissue is highly sensitive to depletion of cellular glutathione that can~~
42
43 268 ~~result in inflammation and cell apoptosis.~~

44
45 269 In this study we demonstrated that the use of BSS at 2.7 °C during
46
47 270 phacoemulsification is able to reduce the onset of inflammatory reaction after cataract
48
49 271 surgery, as demonstrated by the reduction of flare, pain and conjunctival hyperemia 1
50
51 272 day after treatment. Our findings demonstrated the advantage of cold treatment in
52
53 273 reducing the immediate negative impact of intervention on eye tissues, whereas at 3,
54
55 274 5, and 30 day after cataract surgery no significant difference between the two groups
56
57 275 occurred, suggesting that cold BSS could reduce the local inflammation in the early
58
59 276 post-surgical period. The early phase of recovery is the most critical, representing a

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

277 moment in which the defenses of the tissues from inflammation could fail in some
278 patients, hence the application of the cooling procedure investigated in this study
279 could be important.

Taken together our *in vivo* data highlight the advantage of cold irrigating eye solution usage in preventing ~~patients—discomfort~~ post-surgical ocular damage and thus lowering the clinical scores of inflammation already after 1 day. This is ascribable, **at least in part**, to the reduction of the temperature within phacoemulsification procedure as cold irrigation decreases the ultrasound thermal rise at the tip of the phacoemulsifier, ~~which that~~ contributes to cellular damage and inflammation. In fact, the anterior chamber temperature variation, measured with a thermal camera during phacoemulsification in presence of cold solution, was about of 6-8 degrees less than ~~that-the variation~~ measured in presence of ultrasounds and room temperature solution (data not shown). **However the authors do not rule out that high voltage ultrasounds generated by phacoemulsifier could cause the cellular damage by additional mechanisms other than heat generation. Indeed, using the cold BSS the cellular damage has not been completely prevented (24) suggesting that by the cooling procedure it is possible to reduce part of the harm attributable to a thermic effect of the phacoemulsification, but that the cellular damage could also be due to other temperature-independent mechanisms, such as cavitation (43).**

~~It is well known that temperature is an~~ In addition to the reduction of damaging heating, temperature cooling could exert a beneficial metabolic effect. In fact, an important parameter of tissue metabolism **is the temperature**. Mitochondria are the primary source of cellular energy and their activity is central to the determination of metabolic rate and, consequently, the generation of metabolic heat (44). The environmental temperature can modulate the mitochondrial energy metabolism (45). Indeed, the cold temperature influenced the metabolism of human keratinocytes by enhancing the oxidative metabolism of mitochondria and not the glycolysis (45). This increment of mitochondrial activity **supporting homeostatic thermogenesis** was accompanied by a metabolic switch toward a catabolic quiescent phenotype **and was**

1
2
3 306 triggered by 33°C a drop of only 4 degrees compared to basal temperature. Pamenter
4
5 307 ~~et al. demonstrated that mitochondrial respiration is more tightly coupled to the H⁺~~
6
7 308 ~~gradient in the response to cold, indicating that mitochondrial activity is more~~
8
9 309 ~~efficient at the 28°C rather than at 37°C. The authors conclude that the enhancement~~
10
11 310 ~~of mitochondrial function at colder temperature contributes to energy conservation~~
12
13 311 ~~and increases cellular viability in hypoxic murine brain demonstrating the therapeutic~~
14
15 312 ~~effect of hypothermia in a neurological disorder.~~ Based on these considerations it is
16
17 313 plausible that the use of refrigerated irrigation solution during phacoemulsification,
18
19 314 ~~mimicking a condition of hypothermia lowering the anterior chamber temperature,~~
20
21 315 could enhance the efficiency of mitochondrial respiration in order to generate heat
22
23 316 and maintain the physiological intracellular temperature; the consequent increased
24
25 317 energy production would ameliorate the adaptability of corneal endothelial
26
27 318 mitochondria to tissue stress due to surgery and could increase cell viability. As a
28
29 319 consequence of a reduced damage to the cells, the cell death inducing a local acute
30
31 320 inflammation is ~~lowered decreasead~~. Indeed, patients belonging to Group 2 reported a
32
33 321 ~~decreased lower~~ degree of anterior chamber flare, pain and conjunctival hyperemia,
34
35 322 used as signs of inflammation (17).

36
37 323 ~~Indeed,~~ The chemical effects of ultrasound in aqueous solution are attributed to
38
39 324 acoustic cavitation, which refers to the formation, growth and collapse of small gas
40
41 325 bubbles in liquids (46). The high temperature and pressure resulting from a collapsing
42
43 326 gas bubble leads to thermal dissociation of water and a reactive oxygen species
44
45 327 (ROS) overproduction (46), whereas in case of ultrasonic intensity below cavitation
46
47 328 threshold ROS is not generated (47). ~~Indeed, the generation of free radicals, through~~
48
49 329 ~~the phenomenon of sonolysis (H₂O → ·OH + ·H) (48), and thus the consequent~~
50
51 330 ~~oxidative stress, are additional harmful factors for corneal endothelium can be~~
52
53 331 ~~damaged during phacoemulsification as another harmful factor is oxidative stress~~
54
55 332 ~~which is due to the generation of free radicals through the phenomenon of sonolysis~~
56
57 333 ~~(H₂O → ·OH + ·H) (46).~~

1
2
3 334 An attempt to prevent ROS formation has been proposed by Praveen et al. using a
4 moderately cooled BSS Plus (supplemented with glutathione) without any detectable
5 335 effect on post-operative corneal parameters and on inflammation (49). Therefore the
6 possible impact of ROS generation remains to be investigated. This could be ascribed
7 336 to the composition of the BSS Plus; Even if ocular tissue is highly sensitive to
8 depletion of cellular glutathione that can result in inflammation and cell apoptosis,
9 337 the possible beneficial effect of glutathione supplementation in the BSS solution has
10 not been proven suggesting that . as antioxidant molecule maintains the junctional
11 338 complexes of corneal endothelial cells and protects the blood-aqueous barrier
12 integrity acting as inflammatory response modulator. Indeed ocular tissue is highly
13 339 sensitive to depletion of cellular glutathione that can result in inflammation and cell
14 apoptosis.
15 340
16 341
17 342
18 343
19 344
20 345
21 346
22 347
23 348
24 349
25 350
26 351
27 352
28 353
29 354
30 355
31 356
32 357
33 358
34 359
35 360
36 361
37 362
38 363
39 364
40 365
41 366
42 367
43 368
44 369
45 370
46 371
47 372
48 373
49 374
50 375
51 376
52 377
53 378
54 379
55 380
56 381
57 382
58 383
59 384
60 385

The temperature abatement of the anterior chamber that in our study significantly decreased the damage of corneal cells (24) could possibly decrease ROS production thus reducing tissue oxidative stress and, subsequently, the ROS-mediated inflammation. Moreover, as reported for the reduced cleaning efficiency of ultrasonic cleaning solutions among which acids and alkaline salts (49) (50), the cavitation intensity in presence of BSS solution, that is a balanced salt solution, could be different from the intensity cavitation of water. As consequence, the ROS generation could be atypical in presence of a cold BSS solution as well as the types of ROS produced, their kinetic/homeostasis (50) and diffusion (51). Also in this case the reduced amount of ROS leads to a decrease damage of the tissue and less to a lighter inflammatory response. Moreover, the benefic effects of refrigerated intraocular irrigation solution could be due to the vasoconstriction, induced by cold, which could reduce the release of the pro-inflammatory mediators (34) during cataract surgery, similarly to the nonsteroidal antiinflammatory drugs effects (52).

1
2
3 362 **CONCLUSIONS**
4
5

6 363 ~~One of the major issues in the cataract procedures is the protection of endothelial~~
7
8 364 ~~cells; thus, new surgical alternatives to achieve this goal continue to be sought. In~~
9
10 365 ~~light of~~ Supported by our previous encouraging results that have demonstrated the
11
12 366 protective role of the cold irrigating solution in reducing endothelial cells damage,
13
14 367 ~~and based on the results of the present study we now could affirm~~ believe that the use
15
16 368 of this new technique could be definitely recommended in cataracts as it also
17
18 369 contributes to reduce patients discomfort preventing a local inflammation ~~in the early~~
19
20 370 ~~post-surgical period.~~
21
22

23 371
24
25 372
26
27
28 373
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 374 **REFERENCES**

- 4
5
6 375 1. Tauqir MZ, Chaudhry TA, Mumtaz S, Ahmad K. Knowledge of patients' visual
7 376 experience during cataract surgery: a survey of eye doctors in Karachi, Pakistan.
8 377 BMC Ophthalmol. 2012; 12: 55.
9
10
11 378 2. Lee CM, Afshari NA. The global state of cataract blindness. Curr Opin
12 379 Ophthalmol. 2017; 28: 98–103.
13
14
15 380 3. Allen D, Vasavada A. Cataract and surgery for cataract. BMJ. 2006; 333: 128–
16 381 32.
17
18
19 382 4. Meduri A, Urso M, Signorino GA, Rechichi M, Mazzotta C, Kaufman S.
20 383 Cataract surgery on post radial keratotomy patients. Int J Ophthalmol. 2017; 10:
21 384 1168–70.
22
23
24 385 5. GÜngör SG, Bulam B, Akman A, Çolak M. Comparison of intracameral
25 386 dexamethasone and intracameral triamcinolone acetonide injection at the end of
26 387 phacoemulsification surgery. Indian J Ophthalmol. 2014; 62: 861–4.
27
28
29 388 6. Kumar DA, Agarwal A, Jacob S, Lamba M, Packialakshmi S, Meduri A.
30 389 Combined surgical management of capsular and iris deficiency with glued
31 390 intraocular lens technique. J Refract Surg Thorofare NJ 1995. 2013; 29: 342–7.
32
33
34 391 7. Mokhtarzadeh A, Kaufman SC, Koozekanani DD, Meduri A. Delayed
35 392 presentation of retained nuclear fragment following phacoemulsification cataract
36 393 extraction. J Cataract Refract Surg. 2014; 40: 671–4.
37
38
39 394 8. Vasavada A, Singh R. Phacoemulsification in eyes with posterior polar cataract.
40 395 J Cataract Refract Surg. 1999; 25: 238–45.
41
42 396 9. Igarashi T, Ohsawa I, Kobayashi M, et al. Hydrogen prevents corneal endothelial
43 397 damage in phacoemulsification cataract surgery. Sci Rep. 2016; 6: 31190.
44
45
46 398 10. Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of
47 399 ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery.
48 400 J Cataract Refract Surg. 1999; 25: 699–704.
49
50
51 401 11. Herbort CP, Jauch A, Othenin-Girard P, Tritten JJ, Fsadni M. Diclofenac drops
52 402 to treat inflammation after cataract surgery. Acta Ophthalmol Scand. 2000; 78:
53 403 421–4.
54
55
56 404 12. Cousins SW, McCabe MM, Danielpour D, Streilein JW. Identification of
57 405 transforming growth factor-beta as an immunosuppressive factor in aqueous
58 406 humor. Invest Ophthalmol Vis Sci. 1991; 32: 2201–11.
59
60

- 1
2
3 407 13. Herbort CP, Jauch A, Othenin-Girard P, Tritten J-J, Fsadni M. Diclofenac drops
4 408 to treat inflammation after cataract surgery. *Acta Ophthalmol Scand.* 2000; 78:
5 409 421–4.
6 410
7
8 410 14. Shah TJ, Conway MD, Peyman GA. Intracameral dexamethasone injection in the
9 411 treatment of cataract surgery induced inflammation: design, development, and
10 412 place in therapy. *Clin Ophthalmol Auckl NZ.* 2018; 12: 2223–35.
11 413
12
13 413 15. Feizi S. Corneal endothelial cell dysfunction: etiologies and management. *Ther*
14 414 *Adv Ophthalmol.* 2018; 10: 2515841418815802.
15 415
16
17 415 16. Porela-Tiihonen S, Kaarniranta K, Kokki M, Purhonen S, Kokki H. A
18 416 prospective study on postoperative pain after cataract surgery. *Clin Ophthalmol*
19 417 *Auckl NZ.* 2013; 7: 1429–35.
20 418
21
22 418 17. Malik A, Sadafale A, Gupta YK, Gupta A. A comparative study of various
23 419 topical nonsteroidal anti-inflammatory drugs to steroid drops for control of post
24 420 cataract surgery inflammation. *Oman J Ophthalmol.* 2016; 9: 150–6.
25 421
26
27 421 18. Juthani VV, Clearfield E, Chuck RS. Non-steroidal anti-inflammatory drugs
28 422 versus corticosteroids for controlling inflammation after uncomplicated cataract
29 423 surgery. *Cochrane Database Syst Rev.* 2017; 7: CD010516.
30 424
31
32 424 19. Gonzales JA, Gritz DC, Channa R, Quinto GG, Kim A, Chuck RS. Non-steroidal
33 425 anti-inflammatory drugs versus corticosteroids for controlling inflammation after
34 426 uncomplicated cataract surgery. *Cochrane Database Syst Rev [Internet].* 2013
35 427 [cited 2020 Sep 2]; Available from:
36 428 <http://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010516/full>
37 429
38 429
39
40 429 20. Pacifico RL. Ultrasonic energy in phacoemulsification: mechanical cutting and
41 430 cavitation. *J Cataract Refract Surg.* 1994; 20: 338–41.
42 431
43
44 431 21. Li S, Chen X, Zhao J, Xu M, Yu Z. Isolated Capsulorhexis Flap Technique in
45 432 Femtosecond Laser-Assisted Cataract Surgery to Protect the Corneal Endothelial
46 433 Cells. *J Investig Surg Off J Acad Surg Res.* 2019; 32: 35–8.
47 434
48
49 434 22. Arshinoff SA. Dispersive-cohesive viscoelastic soft shell technique. *J Cataract*
50 435 *Refract Surg.* 1999; 25: 167–73.
51 436
52
53 436 23. Rubowitz A, Assia EI, Rosner M, Topaz M. Antioxidant protection against
54 437 corneal damage by free radicals during phacoemulsification. *Invest Ophthalmol*
55 438 *Vis Sci.* 2003; 44: 1866–70.
56 439
57
58 439 24. Meduri A, Aragona P, Testagrossa B, et al. An Alternative Approach to Cataract
59 440 Surgery Using BSS Temperature of 2.7 °C. *Appl Sci.* 2020; 10: 2682.
60 441

- 1
2
3 441 25. Chylack LT, Wolfe JK, Singer DM, et al. The Lens Opacities Classification
4 442 System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol
5 443 Chic Ill 1960. 1993; 111: 831–6.
6 444
7
8 444 26. Assaf A, Roshdy MM. Comparative analysis of corneal morphological changes
9 445 after transversal and torsional phacoemulsification through 2.2 mm corneal
10 446 incision. Clin Ophthalmol Auckl NZ. 2013; 7: 55–61.
11 447
12
13 447 27. Kanellopoulos AJ, Asimellis G. Standard manual capsulorhexis / Ultrasound
14 448 phacoemulsification compared to femtosecond laser-assisted capsulorhexis and
15 449 lens fragmentation in clear cornea small incision cataract surgery. Eye Vis Lond
16 450 Engl. 2016; 3: 20.
17 451
18
19 451 28. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis
20 452 Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature
21 453 for reporting clinical data. Results of the First International Workshop. Am J
22 454 Ophthalmol. 2005; 140: 509–16.
23 455
24
25 455 29. Pohlmann D, Schlickeiser S, Metzner S, Lenglinger M, Winterhalter S, Pleyer U.
26 456 Different composition of intraocular immune mediators in Posner-Schlossman-
27 457 Syndrome and Fuchs' Uveitis. PLOS ONE. 2018; 13: e0199301.
28 458
29
30 458 30. Wentz SM, Price F, Harris A, Siesky B, Ciulla T. Efficacy and safety of
31 459 bromfenac 0.075% formulated in DuraSite for pain and inflammation in cataract
32 460 surgery. Expert Opin Pharmacother. 2019; 20: 1703–9.
33 461
34
35 461 31. Sudhir RR, Murthy PP, Tadepalli S, et al. Ocular Spot Fluorometer Equipped
36 462 With a Lock-In Amplifier for Measurement of Aqueous Flare. Transl Vis Sci
37 463 Technol. 2018; 7: 32–32.
38 464
39
40 464 32. Machata AM, Kabon B, Willschke H, et al. A new instrument for pain
41 465 assessment in the immediate postoperative period. Anaesthesia. 2009; 64: 392–8.
42 466
43
44 466 33. Thong ISK, Jensen MP, Miró J, Tan G. The validity of pain intensity measures:
45 467 what do the NRS, VAS, VRS, and FPS-R measure? Scand J Pain. 2018; 18: 99–
46 468 107.
47 469
48
49 469 34. Coelho RP, Biaggi RH, Jorge R, Rodrigues M de LV, Messias A. Clinical study
50 470 of pain sensation during phacoemulsification with and without cryoanalgesia. J
51 471 Cataract Refract Surg. 2015; 41: 719–23.
52 472
53
54 472 35. Sakamoto E, Ishida W, Sumi T, et al. Evaluation of offset of conjunctival
55 473 hyperemia induced by a Rho-kinase inhibitor; 0.4% Ripasudil ophthalmic
56 474 solution clinical trial. Sci Rep. 2019; 9: 3755.
57 475
58
59
60

- 1
2
3 475 36. Takamura E, Uchio E, Ebihara N, et al. Japanese guidelines for allergic
4 476 conjunctival diseases 2017. *Allergol Int Off J Jpn Soc Allergol.* 2017; 66: 220–9.
6
7 477 37. Terao E, Nakakura S, Fujisawa Y, et al. Time Course of Conjunctival Hyperemia
8 478 Induced by a Rho-kinase Inhibitor Anti-glaucoma Eye Drop: Ripasudil 0.4%.
9 479 *Curr Eye Res.* 2017; 42: 738–42.
11
12 480 38. Terao E, Nakakura S, Fujisawa Y, et al. Time course of conjunctival hyperemia
13 481 induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot,
14 482 comparative study versus ripasudil 0.4%. *BMJ Open Ophthalmol.* 2020; 5:
15 483 e000538.
17
18 484 39. Walkow T, Anders N, Klebe S. Endothelial cell loss after phacoemulsification:
19 485 relation to preoperative and intraoperative parameters. *J Cataract Refract Surg.*
20 486 2000; 26: 727–32.
22
23 487 40. Findl O, Amon M, Petternel V, Kruger A. Early objective assessment of
24 488 intraocular inflammation after phacoemulsification cataract surgery. *J Cataract*
25 489 *Refract Surg.* 2003; 29: 2143–7.
27
28 490 41. Stănilă D-M, Florea A-M, Stănilă A, Panga AA. Endothelial cells loss to the
29 491 hyperopic patients during phacoemulsification. *Romanian J Ophthalmol.* 2017;
30 492 61: 256–60.
32
33 493 42. Feizi S. Corneal endothelial cell dysfunction: etiologies and management. *Ther*
34 494 *Adv Ophthalmol* [Internet]. 2018 [cited 2020 Apr 20]; 10. Available from:
35 495 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293368/>
36 496
37
38 496 43. Lai J, Pittelkow MR. Physiological effects of ultrasound mist on fibroblasts. *Int J*
39 497 *Dermatol.* 2007; 46: 587–93.
41
42 498 44. Pamerter ME, Lau GY, Richards JG. Effects of cold on murine brain
43 499 mitochondrial function. *PloS One.* 2018; 13: e0208453.
45
46 500 45. Viano M, Alotto D, Aillon A, Castagnoli C, Silvagno F. A thermal gradient
47 501 modulates the oxidative metabolism and growth of human keratinocytes. *FEBS*
48 502 *Open Bio.* 2017; 7: 1843–53.
50
51 503 46. Rehman MU, Jawaid P, Uchiyama H, Kondo T. Comparison of free radicals
52 504 formation induced by cold atmospheric plasma, ultrasound, and ionizing
53 505 radiation. *Arch Biochem Biophys.* 2016; 605: 19–25.
55
56 506 47. Rehman MU, Jawaid P, Uchiyama H, Kondo T. Comparison of free radicals
57 507 formation induced by cold atmospheric plasma, ultrasound, and ionizing
58 508 radiation. *Arch Biochem Biophys.* 2016; 605: 19–25.
59
60

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

- 509 48. Igarashi T, Ohsawa I, Kobayashi M, et al. Effects of Hydrogen in Prevention of
510 Corneal Endothelial Damage During Phacoemulsification: A Prospective
511 Randomized Clinical Trial. *Am J Ophthalmol.* 2019; 207: 10–7.
- 512 49. Praveen MR, Vasavada AR, Shah R, Vasavada VA. Effect of room temperature
513 and cooled intraocular irrigating solution on the cornea and anterior segment
514 inflammation after phacoemulsification: a randomized clinical trial. *Eye Lond*
515 *Engl.* 2009; 23: 1158–63.
- 516 50. Ray PD, Huang B-W, Tsuji Y. Reactive oxygen species (ROS) homeostasis and
517 redox regulation in cellular signaling. *Cell Signal.* 2012; 24: 981–90.
- 518 51. Chung Y-H, Xia J, Margulis CJ. Diffusion and residence time of hydrogen
519 peroxide and water in crowded protein environments. *J Phys Chem B.* 2007; 111:
520 13336–44.
- 521 52. Epstein RL, Laurence EP. Effect of topical diclofenac solution on discomfort
522 after radial keratotomy. *J Cataract Refract Surg.* 1994; 20: 378–80.

1
2
3 525 **Conflict of interest statement**
4

5
6 526 The authors have no conflicts of interest to declare.
7

8
9 527
10 528 **Funding statement**
11

12 529 The authors declare not have received any funding.
13
14 530
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

	Patient whose eye were irrigated with BSS at ~20° C (Group 1) n = 110	Patient whose eye were irrigated with BSS at 2.7° C (Group 2) n = 104	
Gender			n.s.
Male	52	49	
Female	58	55	
Age (years)	69.02 ± 6	68.65 ± 7	n.s.
Nationality	italian	italian	n.s.
Education	0	0	n.s.
Primary	9	11	
Secondary	73	68	
Higher	28	25	

Table 1. A descriptive table of variables by groups. $p > 0.05$ (n.s.) Group 2 vs Group 1 before and after treatments.

Variables	Group 1 (patients who received BSS solution at with BSS at ~20° C) n = 110	Group 2 (patients who received BSS solution at 2.7°C) n = 104	p value
FLARE (photons/milliseconds)			
at 1 day after surgery	2.83 ± 0.41	1.68 ± 0.18	0.043
at 3 day after surgery	1.91 ± 0.61 ^a	1.18 ± 0.24 ^b	0.172
at 5 day after surgery	0.55 ± 0.31 ^c	0.53 ± 0.27 ^c	0.451
at 30 days after surgery	0.51 ± 0.29 ^d	0.46 ± 0.31 ^d	0.293
VAS (units)			
at 1 day after surgery	6.72 ± 1.98	3.35 ± 2.12	<0.001
at 3 day after surgery	3.64 ± 1.39 ^a	2.85 ± 1.55 ^a	0.273
at 5 day after surgery	1.82 ± 0.95 ^b	1.65 ± 1.12 ^b	0.390
at 30 days after surgery	1.02 ± 0.77 ^c	0.95 ± 0.5 ^c	0.426
CONJUNCTIVAL HYPEREMIA (units)			
at 1 day after surgery	2.2 ± 0.77	1.5 ± 0.5	<0.0001

at 3 day after surgery	1.1 ± 0.51^a	1.1 ± 0.49^b	0.250
at 5 day after surgery	0.8 ± 0.62^c	0.7 ± 0.62^c	0.110
at 30 days after surgery	0.6 ± 0.5^d	0.5 ± 0.5^d	0.139

Table 2. Comparison of inflammation scores (anterior chamber flare, VAS, visual analogue score and conjunctival hyperemia) between the two groups. p value reported in table refers to intergroup comparison, and p values for intragroup comparison at different times after surgery are as follows: ^a p = 0.03 (1 day vs 3 day); ^b p = 0.04 (1 day vs 3 day); ^c p < 0.0001 (1 day vs 5 day); ^d p < 0.0001 (1 day vs 30 day) for flare; ^a p < 0.001 (1 day vs 3 day); ^b p < 0.0001 (1 day vs 5 day); ^c p < 0.0001 (1 day vs 30 day) for VAS; ^a p = 0.015 (1 day vs 3 day); ^b p = 0.01 (1 day vs 3 day); ^c p < 0.0001 (1 day vs 5 day); ^d p < 0.0001 (1 day vs 30 day) for conjunctival hyperemia.